Vertex Pharmaceuticals Incorporated (VRTX) Guidance & Earnings Results
On 2026-08-03 Vertex Pharmaceuticals Incorporated raised guidance: "FY2026 revenue raised to $13.1B-$13.2B from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VRTXVertex Pharmaceuticals IncorporatedFollow VRTX — free
—
Price chart with a free account
- Market cap
- 132.8B
- P/E TTM
- 30.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 3 Aug 26 | Raised | FY2026 revenue raised to $13.1B-$13.2B from $12.95B-$13.1B · full year |
| 4 May 26 | Reaffirmed | Revenue $12.95-13.1B; non-CF product revenue ≥$500M; combined GAAP R&D/AIPR&D/SG&A $6.3-6.45B; non-GAAP effective tax rate 19.5-20.5% · full year |
| 12 Feb 26 | Raised | FY26 total revenue guidance $12.95-13.1B; non-CF product revenue $500M+; combined GAAP R&D, AIPR&D and SG&A $6.3-6.45B; non-GAAP effective tax rate 19.5-20.5% |
| 3 Nov 25 | Raised | Revenue guidance raised to $11.9-12.0B from $11.85-12.0B; non-GAAP tax rate lowered to 17-18% from 20.5-21.5% · full year |
| 4 Aug 25 | Reaffirmed | FY2025 revenue $11.85-12.0B; combined GAAP R&D, AIPR&D, SG&A $5.55-5.7B; combined non-GAAP R&D, AIPR&D, SG&A $4.9-5.0B; non-GAAP effective tax rate 20.5-21.5% · full year |
Vertex Pharmaceuticals Incorporated — questions
- What guidance did Vertex Pharmaceuticals Incorporated give?
- On 2026-08-03: "FY2026 revenue raised to $13.1B-$13.2B from $12.95B-$13.1B"
- When does Vertex Pharmaceuticals Incorporated report earnings?
- Vertex Pharmaceuticals Incorporated's next earnings report is expected on 2026-11-02.
Every figure on this page comes from Vertex Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.